Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Venous thromboembolism (VTE) represents a major challenge in the management of
patients with cancer. The malignant phenotype is associated with derangements in the …

Venous thromboembolism (VTE) is a highly prevalent complication of malignancy with
emerging changes in incidence, diagnosis and treatment paradigms. This manuscript …

Cancer and its treatments are well-recognized risk factors for venous thrombo-embolism
(VTE). Although solid tumors have historically been associated with VTE, more recent data …

Purpose Patients with cancer are increasingly at risk for venous thromboembolism (VTE).
Rates of VTE, however, vary markedly among patients with cancer. Design This review …

Venous thromboembolism (VTE) is a common complication in patients with malignant
disease. Emerging data have enhanced our understanding of cancer-associated …

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in patients
with cancer. The risk of VTE varies over the natural history of cancer, with the highest risk …

The incidence of venous thromboembolism (VTE) in cancer patients may have changed in
the past decade, possibly due to novel cancer therapies, improved survival, and high …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …